Please assess the completion status of the following clinical trial:

Trial Title: Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Age \> 18 years~* Adult, non-gravid patients with malignancy and symptomatic loculated pleural effusion who has undergone percutaneous drainage will be eligible to participate. A loculated effusion is defined as an effusion whose contents cannot be completely drained at the time of initial catheter placement as documented by the initial imaging guided procedure or within 48 hours of catheter placement by chest radiography. Malignant cells need not be found within the pleural fluid.~Exclusion Criteria:~* Active internal bleeding, involving intracranial and retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts~* History of stroke within 3 months~* Intracranial neoplasm, arteriovenous malformation, or aneurysm.~* Uncorrectable bleeding diathesis (INR \> 1.5 despite therapy)~* Recent intracranial or intraspinal surgery or trauma~* Pregnancy (positive pregnancy test)~* Severe uncontrolled hypertension~* Documented empyema~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Participation in another simultaneous medical investigation or trial~* Participation in another clinical investigation within previous 30 days of catheter placement~* Prior enrollment in the study~* Known allergy to TNK or any of its components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): Loculated pleural effusion infused with normal saline twice a day for three days.
- TNKase (Type: ACTIVE_COMPARATOR): Loculated pleural effusion infused with TNK twice a day for three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).